Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on "Dr.
Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India."
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | PRANAV PRIMLANI pranav.primlani@drreddys.com (Ph: +91- 9381905796 |
Reddy's Laboratories Gets Emergency Use Authorisation for Sputnik V in India
Hyderabad, India. April 13, 2021- Dr.
Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) today announced that it has received the
permission from the Drug Controller General of India (DCGI) to import the Sputnik vaccine into India for restricted use in
emergency situations as per the provisions of the New Drug and Clincial Trials rules, 2019 under the Drugs and Cosmetics Act.
In September 2020, Dr. Reddy's had partnered
with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and distribute the vaccine in India.
In addition to the trials conducted in Russia by RDIF. Phase II / III clinical trials of the vaccine were carried out by Dr. Reddy's
Dr Reddy's Laboratories Co-chairman and
managing director GV Prasad said, "We are very pleased to obtain the emergency use authorsation for Sputnik V in India.
With the rising cases in India, vaccination is the most effective tool in our battle against COVID-19. This will enable us to contribute
to our nation's effort of vaccinating a signficant proportion of our population."
Sputnik V is now approved for use in 60 countries
around the world. It ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government
regulators. Sputnik V uses two different vectors for the two shots in a course of vaccination. The efficacy of Sputnik V was determined
to be 91.6% as per a published article in the Lancet, one of the world's oldest and most respected medical journals.
Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products
and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's
operates in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management's current views and
assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ
materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of
context, the words "may", "will", "should", "expects", "plans", "intends",
"anticipates", "believes", "estimates", "predicts", "potential", or "continue"
and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those
in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit
defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality
and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and
regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including
related integration issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our
customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread
illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the
Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"
sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information